You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 24, 2025

Claims for Patent: 10,702,576

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,702,576

Title:	Stable formulations of linaclotide
Abstract:	The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Inventor(s):	Mo; Yun (Commack, NY), Fretzen; Angelika (Somerville, MA), Cali; Brian (Arlington, MA), Dedhiya; Mahendra (Pomona, NY)
Assignee:	IRONWOOD PHARMACEUTICALS, INC. (Cambridge, MA) FOREST LABORATORIES HOLDINGS LIMITED (Hamilton, BM)
Application Number:	16/250,237
Patent Claims:	1. A method of treating a gastrointestinal disorder in a patient, the method comprising administering to a patient in need thereof, a pharmaceutical composition comprising linaclotide, Ca.sup.2+ or pharmaceutically acceptable salt thereof and histidine, wherein the composition has a molar ratio of Ca.sup.2+:histidine of less than 1.5:1 and a molar ratio of histidine:linaclotide is between 120:1 and 80:1, wherein the gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome, chronic constipation, and opioid induced constipation. 2. The method of claim 1, wherein the gastrointestinal disorder is chronic constipation. 3. The method of claim 1, wherein the irritable bowel syndrome is constipation-predominant irritable bowel syndrome. 4. The method of claim 1, wherein the molar ratio of Ca.sup.2+:histidine is between about 1.3:1 and 0.7:1. 5. The method of claim 4, wherein the molar ratio of Ca.sup.2+:histidine is between about 1.1:1 and 0.9:1. 6. The method of claim 1, wherein the molar ratio of Ca.sup.2+:histidine is 0.5:1. 7. The method of claim 1, wherein the pharmaceutical composition has a molar ratio of Ca.sup.2+:linaclotide is about 50:1. 8. The method of claim 1, wherein the molar ratio histidine:linaclotide is about 100:1. 9. The method of claim 1, wherein the molar ratio of histidine:linaclotide is between 110:1 and 90:1 and the molar ratio of Ca.sup.2+:linaclotide is between 60:1 and 20:1. 10. The method of claim 1, wherein the composition further comprises a polymer. 11. The method of claim 10, wherein the polymer is selected from the group consisting of polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA) and a mixture thereof. 12. The method of claim 11, wherein the polymer is polyvinyl alcohol (PVA). 13. The method of claim 12, wherein the composition comprises 1% to 5% by weight of polyvinyl alcohol (PVA). 14. The method of claim 12, wherein the composition comprises 1.5% by weight of polyvinyl alcohol (PVA). 15. The method of claim 1, wherein the composition comprises 0.001 .mu.g to 300 .mu.g of linaclotide. 16. The method of claim 15, wherein the composition comprises 25 .mu.g to 75 .mu.g of linaclotide. 17. The method of claim 16, wherein the composition comprises 50 .mu.g to 75 .mu.g of linaclotide. 18. The method of claim 1, wherein the composition comprises 50 .mu.g to 300 .mu.g of linaclotide. 19. The method of claim 18, wherein the composition comprises 300 .mu.g of linaclotide. 20. The method of claim 1, wherein the molar ratio of histidine to linaclotide is about 100:1, a molar ratio of Ca2+ to linaclotide is about 50:1 and the composition further comprises polyvinyl alcohol (PVA).

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.